RxDoctor Payments Data

Fred Caldwell, MD

Internal Medicine · Poplar Bluff, MONPI 1558308239

Payments from drug & device makers

$1,212in general payments, 2019–2025

Across 80 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$347
  • Novo Nordisk$287
  • Abbott$152
  • Johnson & Johnson$79
  • Astellas Pharma US Inc$65
  • Pfizer$55
  • plus $228 from 11 others

What the payments were for

  • Food & beverage$1,14795%
  • Education$655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,212 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$107,687
Medicare patients
1,162
Services billed
3,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban947$465,719
MounjaroTirzepatide177$199,558
OzempicSemaglutide134$157,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$137,819
JardianceEmpagliflozin156$129,927
Invega SustennaPaliperidone Palmitate28$79,831
JanuviaSitagliptin Phosphate220$74,515
XareltoRivaroxaban128$55,733
Tresiba Flextouch U-100Insulin Degludec89$54,291
ArexvyRsvpref3 Antigen/As01e/Pf192$52,787
MyrbetriqMirabegron113$51,260
GemtesaVibegron190$50,625
TrulicityDulaglutide49$47,554
FarxigaDapagliflozin Propanediol113$47,231
LinzessLinaclotide91$44,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$55$481,7671,002 claims
Lilly USA, LLCMounjaro, Trulicity$52$247,112226 claims
Novo NordiskOzempic, Rybelsus$287$201,142181 claims
Johnson & JohnsonInvega Sustenna, Xarelto$79$135,565156 claims
AbbVieLinzess, Teflaro, Synthroid, Restasis$23$93,390346 claims
MerckJanuvia, Belsomra$12$86,230258 claims
AstraZenecaFarxiga, Symbicort, Brilinta$13$72,332206 claims
Astellas Pharma US IncMyrbetriq$65$51,260113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Poplar Bluff

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →